Candel Therapeutics, Inc.
Candel Therapeutics, Inc. (CADL) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · CADL · as of Sep 30, 2025
Ownership Breakdown
86
Institutional Holders
▲ 3 vs Q2
$115.62M
Total Inst. Value
▼ $948,736 vs Q2
54.90M
Shares Outstanding
freeFloat 86.43%
22.67M
13F Shares Held
▼ 369,009 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
CADL largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
FMR LLC biological products, (no diagnostic substances) | 8.23M | 15.99% | 15.99% | $41.99B | Nov 13, 2025 | ▼ 50 |
ACORN CAPITAL ADVISORS, LLC biological products, (no diagnostic substances) | 2.58M | 5.01% | 5.01% | $13.16B | Nov 17, 2025 | — held |
BLACKROCK, INC. biological products, (no diagnostic substances) | 2.38M | 4.62% | 4.62% | $12.13B | Nov 12, 2025 | ▲ 77.5K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 2.01M | 3.90% | 3.90% | $10.24B | Nov 7, 2025 | ▲ 219.6K |
PORTOLAN CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 1.38M | 2.69% | 2.69% | $7.06B | Nov 13, 2025 | ▼ 237.6K |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 928.2K | 1.80% | 1.80% | $4.73B | Nov 12, 2025 | ▲ 24.2K |
HALTER FERGUSON FINANCIAL INC. biological products, (no diagnostic substances) | 698.0K | 1.36% | 1.36% | $3.56B | Oct 9, 2025 | ▼ 78.5K |
STATE STREET CORP biological products, (no diagnostic substances) | 688.8K | 1.34% | 1.34% | $3.51B | Nov 14, 2025 | ▲ 36.8K |
SANDS CAPITAL VENTURES, LLC biological products, (no diagnostic substances) | 405.8K | 78.82% | 78.82% | $2.07B | Nov 13, 2025 | — held |
NORTHERN TRUST CORP biological products, (no diagnostic substances) | 306.8K | 59.58% | 59.58% | $1.56B | Nov 14, 2025 | ▲ 18.9K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
19
Increased
+1.09M shares3
New Positions
first time holders20
Decreased
−1.24M shares0
Sold Out
fully exitedNet shares change (top 50)
156.5K
+1.09M / −1.24M
Net new holders
+2
3 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
CADL insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
9
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Manning Paul B director | Mar 31, 2026 | Award | 4,618 | $4.90 | $22.6K | 4.6K | Form 4 ↗ |
PAPA JOSEPH C director | Mar 31, 2026 | Award | 2,795 | $4.90 | $13.7K | 2.8K | Form 4 ↗ |
Loggia Nicoletta director | Mar 31, 2026 | Award | 779 | $4.90 | $3.8K | 779 | Form 4 ↗ |
Manning Paul B director | Feb 23, 2026 | Purchase | 550,458 | $5.45 | $3.00M | 2.76M | Form 4 ↗ |
Tyagarajan Seshu Chief Technology Officer | Jan 26, 2026 | Award | 154,000 | $6.01 | $925.5K | 154.0K | Form 4 ↗ |
Nichols William Garrett Chief Medical Officer | Jan 26, 2026 | Award | 136,500 | $6.01 | $820.4K | 136.5K | Form 4 ↗ |
Schoch Charles Chief Financial Officer | Jan 26, 2026 | Award | 232,000 | $6.01 | $1.39M | 232.0K | Form 4 ↗ |
Tak Paul Peter Chief Executive Officer | Jan 26, 2026 | Award | 629,000 | $6.01 | $3.78M | 629.0K | Form 4 ↗ |
Barone Francesca Chief Scientific Officer | Jan 26, 2026 | Award | 232,000 | $6.01 | $1.39M | 232.0K | Form 4 ↗ |
Nichols William Garrett Chief Medical Officer | Jul 28, 2025 | Sale | 937 | $6.98 | $6.5K | 52.5K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Candel Therapeutics, Inc. (CADL) is primarily owned by institutional investors, who hold approximately 41.3% of total shares outstanding. Company insiders own approximately 13.57%, while retail and public investors account for the remaining 45.14%.
The largest institutional shareholder of Candel Therapeutics, Inc. is FMR LLC, holding approximately 8.23 million shares — equal to 15.99% of outstanding shares — as of September 30, 2025.
A total of 86 institutional investors currently hold CADL stock, with a combined institutional value of approximately $115,621,483 as of the most recent 13F filing period.
Frequently asked questions
CADL ownershipCandel Therapeutics, Inc. (CADL) is primarily owned by institutional investors, who hold approximately 41.3% of shares. The largest shareholder is FMR LLC with a 15.99% stake. Company insiders hold 13.57%. Data sourced from SEC Form 13F as of September 30, 2025.